LDBA.F H. LUNDBECK A/S SER.B DK1

Healthcare Pharmaceuticals Frankfurt Exchange
9.93 EUR
Close of Nov 12, 2026
3.95 8.24
Market cap
EUR 7.87B
P/E
14.4x
P/B
2.16x
ROE
19.2%
Dividend yield
1.87%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LDBA.F undervalued?

Graham number
Price9.93
Graham value8.44
Premium17.6%

LDBA.F trades 17.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

H. LUNDBECK A/S SER.B DK1 fundamental analysis

No fundamental analysis for H. LUNDBECK A/S SER.B DK1 yet.

H. LUNDBECK A/S SER.B DK1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About H. LUNDBECK A/S SER.B DK1

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Ci…

Full company profile